open access

Vol 25, No 3 (2020)
Original research articles
Published online: 2020-05-01
Submitted: 2019-12-21
Get Citation

Impact of Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

Felipe Couñago, Claudio Martínez-Ballesteros, Carlos Artigas, Ana Aurora Díaz-Gavela, Luis Leonardo Gómez, María Eugenia Lillo-García, José Reinaldo Chicharo, Manuel Recio, Antonio Maldonado, Israel J. Thuissard, Cristina Andreu-Vázquez, David Sanz-Rosa, Antonio José Conde-Moreno, Francisco José Marcos, Sofía Sánchez García, Juan Ignacio Martínez-Salamanca, Joaquin Carballido-Rodríguez, Javier Hornedo, Elia del Cerro
DOI: 10.1016/j.rpor.2020.03.024
·
Rep Pract Oncol Radiother 2020;25(3):405-411.

open access

Vol 25, No 3 (2020)
Original research articles
Published online: 2020-05-01
Submitted: 2019-12-21

Abstract

Aim

To evaluate whether positron-emission tomography/computed tomography with 68Ga-PSMA (68Ga-PSMA PET/CT) influences the therapeutic management of patients with primary or recurrent prostate cancer (PCa).

Background

Although 68Ga-PSMA PET/CT is one of the best options for staging or restaging patients with PCa, its availability is still very limited in Spain. The present study reports the results of the first group of patients in Spain who underwent 68Ga-PSMA PET/CT imaging.

Materials and methods

All patients (n = 27) with a histological diagnosis of PCa who underwent 68Ga-PSMA PET/CT prior to the definitive treatment decision at the only centre with this technology in Spain during 2017–2018 were included. Two nuclear medicine physicians and a radiologist reviewed the imaging studies. The clinical impact was assessed from a theoretical perspective, based on the treatment that would have been applied if no data from the 68Ga-PSMA PET/CT were available.

Results

Most patients (n = 26; 96%) had persistent disease or biochemical recurrence after radical prostatectomy, radiotherapy, or combined treatment. One patient underwent 68Ga-PSMA PET/CT imaging to stage high-risk PCa. Overall, 68Ga-PSMA PET/CT was positive in 19 patients (70.4%). In 68.75% of these patients, none of the other imaging tests—MRI, CT, or bone scans—performed prior to the 68Ga-PSMA PET/CT were able to detect the presence of cancerous lesions. Overall, the findings of the 68Ga-PSMA PET/CT led to a modification of the therapeutic approach in 62.96% of the patients in the study.

Conclusions

68Ga-PSMA PET/CT alters the therapeutic approach in a substantial proportion of patients with PCa.

Abstract

Aim

To evaluate whether positron-emission tomography/computed tomography with 68Ga-PSMA (68Ga-PSMA PET/CT) influences the therapeutic management of patients with primary or recurrent prostate cancer (PCa).

Background

Although 68Ga-PSMA PET/CT is one of the best options for staging or restaging patients with PCa, its availability is still very limited in Spain. The present study reports the results of the first group of patients in Spain who underwent 68Ga-PSMA PET/CT imaging.

Materials and methods

All patients (n = 27) with a histological diagnosis of PCa who underwent 68Ga-PSMA PET/CT prior to the definitive treatment decision at the only centre with this technology in Spain during 2017–2018 were included. Two nuclear medicine physicians and a radiologist reviewed the imaging studies. The clinical impact was assessed from a theoretical perspective, based on the treatment that would have been applied if no data from the 68Ga-PSMA PET/CT were available.

Results

Most patients (n = 26; 96%) had persistent disease or biochemical recurrence after radical prostatectomy, radiotherapy, or combined treatment. One patient underwent 68Ga-PSMA PET/CT imaging to stage high-risk PCa. Overall, 68Ga-PSMA PET/CT was positive in 19 patients (70.4%). In 68.75% of these patients, none of the other imaging tests—MRI, CT, or bone scans—performed prior to the 68Ga-PSMA PET/CT were able to detect the presence of cancerous lesions. Overall, the findings of the 68Ga-PSMA PET/CT led to a modification of the therapeutic approach in 62.96% of the patients in the study.

Conclusions

68Ga-PSMA PET/CT alters the therapeutic approach in a substantial proportion of patients with PCa.

Get Citation

Keywords

Biochemical recurrence; Staging; PSMA; PET/CT; Prostate cancer

About this article
Title

Impact of Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 3 (2020)

Pages

405-411

Published online

2020-05-01

DOI

10.1016/j.rpor.2020.03.024

Bibliographic record

Rep Pract Oncol Radiother 2020;25(3):405-411.

Keywords

Biochemical recurrence
Staging
PSMA
PET/CT
Prostate cancer

Authors

Felipe Couñago
Claudio Martínez-Ballesteros
Carlos Artigas
Ana Aurora Díaz-Gavela
Luis Leonardo Gómez
María Eugenia Lillo-García
José Reinaldo Chicharo
Manuel Recio
Antonio Maldonado
Israel J. Thuissard
Cristina Andreu-Vázquez
David Sanz-Rosa
Antonio José Conde-Moreno
Francisco José Marcos
Sofía Sánchez García
Juan Ignacio Martínez-Salamanca
Joaquin Carballido-Rodríguez
Javier Hornedo
Elia del Cerro

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl